The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

Higher sales of blockbuster cancer drug Keytruda weigh against a 17% slump in sales of HPV vaccine Gardasil Merck's stock ... $9.03 on sales of $64.1 billion to $65.6 billion.

Six analysts surveyed by Zacks expected $15.55 billion. Merck expects full-year earnings in the range of $8.88 to $9.03 per share, with revenue in the range of $64.1 billion to $65.6 billion.

Guidance: Merck expects fiscal year 2025 sales of $64.1 billion-$65.6 billion versus a consensus of $67.31 billion, including a negative impact of foreign exchange of approximately 2% at mid ...

For 2025 Merck, based in , Rahway, New Jersey, expects adjusted earnings to range between $8.88 and $9.03 per share on $64.1 billion to $65.6 billion in sales. Analysts had been projecting ...

Reports Q4 revenue $15.6B, consensus $15.51B. “We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including ...

outperforming the Medical sector's loss of 4.6% and lagging the S&P 500's gain of 1.5%. Analysts and investors alike will be keeping a close eye on the performance of Merck in its upcoming ...

In November, the US ordered 3.1 million courses of Lagevrio for around $2.2 billion, with an option on another 2 million courses. Merck has shipped around 6.4 million courses of Lagevrio around ...